Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.

ABSTRACT:

Background

Romiplostim, a thrombopoietin receptor agonist (TPOra), is a second-line medical treatment option for adults with chronic immune thrombocytopenia (ITP). Clinical trials have shown that romiplostim increases platelet counts, while reducing the risk of bleeding and, in turn, the need for costly rescue medications.

Aims

The objective of this study was to assess the cost effectiveness of romiplostim in the treatment of adult ITP in Ireland, in comparison with eltrombopag and the medical standard of care (SoC).

Methods

A lifetime treatment-sequence cost-utility Markov model with embedded decision tree was developed from an Irish healthcare perspective to compare romiplostim with eltrombopag and SoC. The model was driven by platelet response (platelet count ≥50 ×

SUBMITTER: Lee D 

PROVIDER: S-EPMC3824633 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature